MoonLake CSO-linked entity sells 43,700 shares

Rhea-AI Filing Summary

MoonLake Immunotherapeutics Chief Scientific Officer Kristian Reich reported that JeruCON Beratungsgesellschaft mbH, an entity whose holdings he may be deemed to beneficially own, sold 43,700 Class A ordinary shares on July 20, 2026 at a weighted average price of $20.09 per share under a Rule 10b5-1 trading plan adopted on March 10, 2026. After the sale, JeruCON held 2,764,746 shares indirectly attributable to him, and he also held 35,389 shares directly.

Insider Trade Summary 10b5-1

Net Seller: 43,700 shares

Net Sell 2 txns

Insider Reich Kristian

Role Chief Scientific Officer

Sold 43,700 shs ($878K)

Type	Security	Shares	Price	Value
Sale	Class A ordinary shares, par value $0.0001 per share F1, F2, F3	43,700	$20.09	$878K
holding	Class A ordinary shares, par value $0.0001 per share	--	--	--

Holdings After Transaction: Class A ordinary shares, par value $0.0001 per share — 2,764,746 shares (Indirect, See footnote.); Class A ordinary shares, par value $0.0001 per share — 35,389 shares (Direct)

Footnotes (3)

1. F1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 10, 2026.
2. F2. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $20.00 to $20.25. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
3. F3. Represents the ordinary shares of the Issuer owned by JeruCON Beratungsgesellschaft mbH. Dr. Reich directly (whether through ownership or position) or indirectly through one or more intermediaries, may be deemed for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, to be the indirect beneficial owner of the ordinary shares owned by JeruCON Beratungsgesellschaft mbH.

Key Figures

Shares sold: 43,700 shares Weighted average sale price: $20.09 per share Sale price range: $20.00–$20.25 per share +2 more

5 metrics

Shares sold 43,700 shares Class A ordinary shares sold on July 20, 2026

Weighted average sale price $20.09 per share Average price for 43,700 shares sold on July 20, 2026

Sale price range $20.00–$20.25 per share Range of prices for the multiple sale transactions

Indirect holdings after sale 2,764,746 shares Ordinary shares held by JeruCON Beratungsgesellschaft mbH after the sale

Direct holdings after sale 35,389 shares Shares directly owned by Kristian Reich after the reported activity

Key Terms

Rule 10b5-1 trading plan, weighted average sale price, indirect beneficial owner, Section 16 of the Securities Exchange Act of 1934

4 terms

Rule 10b5-1 trading plan regulatory

"This transaction was executed pursuant to a Rule 10b5-1 trading plan..."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average sale price financial

"The price reported represents the weighted average sale price per share."

indirect beneficial owner regulatory

"may be deemed ... to be the indirect beneficial owner of the ordinary shares"

Section 16 of the Securities Exchange Act of 1934 regulatory

"for purposes of Section 16 of the Securities Exchange Act of 1934, as amended"

A provision of federal securities law that requires company insiders—directors, officers and large shareholders—to publicly report their stock holdings and trades and to surrender any “short-swing” profits from purchases and sales within a six-month window. It acts like a rule that forces leaders to announce their trades and prevents quick buy-sell windfalls, giving investors transparency into insider activity and reducing opportunities for unfair gain.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did MoonLake Immunotherapeutics (MLTX) report for Kristian Reich?

MoonLake Immunotherapeutics reported that an entity associated with Chief Scientific Officer Kristian Reich sold 43,700 Class A ordinary shares. The sale occurred on July 20, 2026 and is reported as an indirect transaction attributed to JeruCON Beratungsgesellschaft mbH.

How many MLTX shares were sold and at what price in the latest Form 4?

The reported transaction involved the sale of 43,700 MLTX shares at a weighted average price of $20.09 per share. The shares were sold in multiple trades at prices ranging from $20.00 to $20.25 per share, as disclosed in the filing footnotes.

Was the MLTX insider sale by Kristian Reich made under a Rule 10b5-1 plan?

Yes, the sale was executed under a Rule 10b5-1 trading plan. The plan was adopted on March 10, 2026, and the filing’s checkbox and footnote both state that the July 20, 2026 transactions were carried out pursuant to this pre-arranged plan.

How many MoonLake Immunotherapeutics (MLTX) shares does Kristian Reich indirectly hold after the sale?

Following the reported sale, JeruCON Beratungsgesellschaft mbH held 2,764,746 MLTX shares, which may be deemed indirectly beneficially owned by Kristian Reich for Section 16 purposes. This figure reflects the indirect position after the July 20, 2026 transaction.

What is Kristian Reich’s direct ownership in MLTX shares after the reported Form 4 transaction?

After the reported activity, Kristian Reich is shown as directly holding 35,389 MLTX Class A ordinary shares. This direct position is listed separately from the 2,764,746 shares held indirectly through JeruCON Beratungsgesellschaft mbH.

Who actually owns the MLTX shares involved in the reported sale linked to Kristian Reich?

The 43,700 MLTX shares sold are owned by JeruCON Beratungsgesellschaft mbH. Reich may be deemed an indirect beneficial owner of these shares for Section 16 purposes, and the Form 4 attributes the transaction to this entity rather than to him personally.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/21/2026 - 06:13 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Reich Kristian

(Last) (First) (Middle)

C/O MOONLAKE IMMUNOTHERAPEUTICS

DORFSTRASSE 29

(Street)

ZUG 6300

(City) (State) (Zip)

SWITZERLAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
MoonLake Immunotherapeutics [ MLTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A ordinary shares, par value $0.0001 per share	07/20/2026		S(1)		43,700	D	$20.09(2)	2,764,746	I	See footnote.(3)
Class A ordinary shares, par value $0.0001 per share								35,389	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 10, 2026.

2. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $20.00 to $20.25. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

3. Represents the ordinary shares of the Issuer owned by JeruCON Beratungsgesellschaft mbH. Dr. Reich directly (whether through ownership or position) or indirectly through one or more intermediaries, may be deemed for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, to be the indirect beneficial owner of the ordinary shares owned by JeruCON Beratungsgesellschaft mbH.

	/s/ Matthias Bodenstedt, Attorney-in-fact for Kristian Reich	07/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)